ecancermedicalscience is an open access cancer journal focused on under-resourced communities. In order to help reduce global inequalities in cancer care and treatment, we provide free access to all articles from the point of publication and we only charge authors who have specific funding to cover publication costs.
The journal considers articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epidemiology, clinical reports, controlled trials (in particular if they are independent or publicly funded trials), health systems, cancer policy and regulatory aspects of cancer care.
Instituto do Câncer do Estado de São Paulo, Brazil
Dr João Glasberg speaks to ecancer about METNET which is a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. He initially talks about the background of the study.
The aim of the study was to evaluate the efficacy and safety of metformin monotherapy in patients with advanced/metastatic well-differentiated NET (WD-NET) of gastroenteropancreatic (GEP) or pulmonary origin.
Dr Glasberg then discusses the methodology and key results of the study. The study indicated that metformin monotherapy offers modest antitumour activity in well-differentiated GEP or lung NET.
Dr Glasberg concludes by discussing how these results can impact the future treatment of neuroendocrine tumours.